Changing paradigm in advanced and metastatic non-small cell lung cancer

Keyphrases

• Lung Cancer 100%
• Metastatic Disease 100%
• Metastatic Non-small Cell Lung Cancer 100%
• Paradigm Change 100%
• Clinical Trials 50%
• Tumor Cells 50%
• Patient Management 50%
• Programmed Death-ligand 1 (PD-L1) 50%
• Driver mutations 50%
• Common Cancers 50%
• Chemoradiation 50%
• Non-small Cell Lung Cancer (NSCLC) 50%
• Up-To-date Information 50%
• Durvalumab 50%
• PACIFIC Trial 50%

Medicine and Dentistry

• Non Small Cell Lung Cancer 100%
• Malignant Neoplasm 66%
• Lung Cancer 66%
• Metastatic Carcinoma 66%
• Clinical Trial 33%
• Tumor Cell 33%
• Chemoradiotherapy 33%
• Durvalumab 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Malignant Neoplasm 66%
• Lung Cancer 66%
• Clinical Trial 33%
• Neoplasm 33%
• Chemoradiation Therapy 33%
• Durvalumab 33%